

Vicky Goh

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3507063/publications.pdf>

Version: 2024-02-01

216
papers

14,062
citations

28736

57
h-index

25983

112
g-index

223
all docs

223
docs citations

223
times ranked

17259
citing authors

#	ARTICLE	IF	CITATIONS
1	The impact of Human Papilloma Virus status on the prediction of head and neck cancer chemoradiotherapy outcomes using the pre-treatment apparent diffusion coefficient. British Journal of Radiology, 2022, 95, 20210333.	1.0	3
2	Exercise prehabilitation during neoadjuvant chemotherapy may enhance tumour regression in oesophageal cancer: results from a prospective non-randomised trial. British Journal of Sports Medicine, 2022, 56, 402-409.	3.1	25
3	Radiomic Analysis of Tumour Heterogeneity Using MRI in Head and Neck Cancer Following Chemoradiotherapy: A Feasibility Study. Frontiers in Oncology, 2022, 12, 784693.	1.3	2
4	Correlation between whole skeleton dual energy CT calcium-subtracted attenuation and bone marrow infiltration in multiple myeloma. European Journal of Radiology, 2022, 149, 110223.	1.2	4
5	Radiomic assessment of oesophageal adenocarcinoma: a critical review of 18F-FDG PET/CT, PET/MRI and CT. Insights Into Imaging, 2022, 13, .	1.6	4
6	State-of-the-art imaging in oesophago-gastric cancer. British Journal of Radiology, 2022, 95, .	1.0	0
7	¹⁸ F FDG PET/CT and Novel Molecular Imaging for Directing Immunotherapy in Cancer. Radiology, 2022, 304, 246-264.	3.6	14
8	Distortion-free 3D diffusion imaging of the prostate using a multishot diffusion-prepared phase-cycled acquisition and dictionary matching. Magnetic Resonance in Medicine, 2021, 85, 1441-1454.	1.9	1
9	Arterial Spin Labeled Perfusion MRI for Assessing Antiangiogenic Therapy: A Step Forward or Just More Spin?. Radiology, 2021, 298, 341-342.	3.6	0
10	Comparison of the diagnostic performance and impact on management of 18F-FDG PET/CT and whole-body MRI in multiple myeloma. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2558-2565.	3.3	13
11	A Multi-Channel Uncertainty-Aware Multi-Resolution Network for MR to CT Synthesis. Applied Sciences (Switzerland), 2021, 11, 1667.	1.3	7
12	Systematic review of research design and reporting of imaging studies applying convolutional neural networks for radiological cancer diagnosis. European Radiology, 2021, 31, 7969-7983.	2.3	14
13	Correlations between DW-MRI and 18 F-FDG PET / CT parameters in head and neck squamous cell carcinoma following definitive chemo-radiotherapy. Cancer Reports, 2021, 4, e1360.	0.6	4
14	Occupational radiation exposure in doctors: an analysis of exposure rates over 25 years. British Journal of Radiology, 2021, 94, 20210602.	1.0	5
15	Apparent diffusion coefficient agreement and reliability using different region of interest methods for the evaluation of head and neck cancer post chemo-radiotherapy. Dentomaxillofacial Radiology, 2021, 50, 20200579.	1.3	6
16	Integrated slice-specific dynamic shimming for whole-body diffusion-weighted MR imaging at 1.5T. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2021, 34, 513-521.	1.1	4
17	Sparse Regression in Cancer Genomics: Comparing Variable Selection and Predictions in Real World Data. Cancer Informatics, 2021, 20, 117693512110562.	0.9	2
18	Initial experience in staging primary oesophageal/gastro-oesophageal cancer with 18F-FDG PET/MRI. European Journal of Hybrid Imaging, 2021, 5, 23.	0.6	7

#	ARTICLE	IF	CITATIONS
19	Radiomic analysis for response assessment in advanced head and neck cancers, a distant dream or an inevitable reality? A systematic review of the current level of evidence. <i>British Journal of Radiology</i> , 2020, 93, 20190496.	1.0	19
20	Heterogeneity in tumours: Validating the use of radiomic features on 18F-FDG PET/CT scans of lung cancer patients as a prognostic tool. <i>Radiotherapy and Oncology</i> , 2020, 144, 72-78.	0.3	35
21	Assessing Radiology Research on Artificial Intelligence: A Brief Guide for Authors, Reviewers, and Readersâ€”From the <i>Radiology</i> Editorial Board. <i>Radiology</i> , 2020, 294, 487-489.	3.6	229
22	Cost-Effectiveness of Immediate Magnetic Resonance Imaging In the Management of Patients With Suspected Scaphoid Fracture: Results From a Randomized Clinical Trial. <i>Value in Health</i> , 2020, 23, 1444-1452.	0.1	9
23	Synthesis and in vivo evaluation of PEG-BPâ€”BaYbF5 nanoparticles for computed tomography imaging and their toxicity. <i>Journal of Materials Chemistry B</i> , 2020, 8, 7723-7732.	2.9	8
24	Predictors of patient preference for either whole body magnetic resonance imaging (WBâ€”MRI) or CT/PETâ€”CT for staging colorectal or lung cancer. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2020, 64, 537-545.	0.9	8
25	A Role for FDG PET Radiomics in Personalized Medicine?. <i>Seminars in Nuclear Medicine</i> , 2020, 50, 532-540.	2.5	12
26	The Image Biomarker Standardization Initiative: Standardized Quantitative Radiomics for High-Throughput Image-based Phenotyping. <i>Radiology</i> , 2020, 295, 328-338.	3.6	1,869
27	Identification of Subtypes of Barrettâ€™s Esophagus and Esophageal Adenocarcinoma Based on DNA Methylation Profiles and Integration of Transcriptome and Genome Data. <i>Gastroenterology</i> , 2020, 158, 1682-1697.e1.	0.6	58
28	Oxygen-enhanced MRI MOLLI T1 mapping during chemoradiotherapy in anal squamous cell carcinoma. <i>Clinical and Translational Radiation Oncology</i> , 2020, 22, 44-49.	0.9	5
29	The Impact of the COVID-19 Pandemic on the Radiology Research Enterprise: Radiology Scientific Expert Panel. <i>Radiology</i> , 2020, 296, E134-E140.	3.6	29
30	Predicting Growth Kinetics in Hereditary Renal Cancer with Diffusion-weighted MRI. <i>Radiology</i> , 2020, 295, 591-592.	3.6	1
31	Molecular Imaging of Bone Metastases and Their Response to Therapy. <i>Journal of Nuclear Medicine</i> , 2020, 61, 799-806.	2.8	37
32	Machine learning to predict early recurrence after oesophageal cancer surgery. <i>British Journal of Surgery</i> , 2020, 107, 1042-1052.	0.1	35
33	Management of chronic headache with referral from primary care to direct access to MRI compared with Neurology services: an observational prospective study in London. <i>BMJ Open</i> , 2020, 10, e036097.	0.8	0
34	Management of chronic headache with referral from primary care to direct access to MRI compared with Neurology services: an observational prospective study in London. <i>BMJ Open</i> , 2020, 10, e036097.	0.8	4
35	Is Response Assessment of Breast Cancer Bone Metastases Better with Measurement of ¹⁸ F-Fluoride Metabolic Flux Than with Measurement of ¹⁸ F-Fluoride PET/CT SUV?. <i>Journal of Nuclear Medicine</i> , 2019, 60, 322-327.	2.8	23
36	Radiomics in esophageal and gastric cancer. <i>Abdominal Radiology</i> , 2019, 44, 2048-2058.	1.0	59

#	ARTICLE	IF	CITATIONS
37	Assessment of the Spatial Heterogeneity of Breast Cancers: Associations Between Computed Tomography and Immunohistochemistry. <i>Biomarkers in Cancer</i> , 2019, 11, 1179299X1985151.	3.6	4
38	Automated Triaging of Adult Chest Radiographs with Deep Artificial Neural Networks. <i>Radiology</i> , 2019, 291, 196-202.	3.6	176
39	Early stage anal margin cancer: towards evidence-based management. <i>Colorectal Disease</i> , 2019, 21, 387-391.	0.7	14
40	Non-invasive classification of non-small cell lung cancer: a comparison between random forest models utilising radiomic and semantic features. <i>British Journal of Radiology</i> , 2019, 92, 20190159.	1.0	32
41	What can artificial intelligence teach us about the molecular mechanisms underlying disease?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 2715-2721.	3.3	15
42	Diagnostic accuracy of whole-body MRI versus standard imaging pathways for metastatic disease in newly diagnosed non-small-cell lung cancer: the prospective Streamline L trial. <i>Lancet Respiratory Medicine</i> , 2019, 7, 523-532.	5.2	50
43	Diagnostic accuracy of whole-body MRI versus standard imaging pathways for metastatic disease in newly diagnosed colorectal cancer: the prospective Streamline C trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 529-537.	3.7	51
44	Loco-regional staging of malignant pleural mesothelioma by integrated 18F-FDG PET/MRI. <i>European Journal of Radiology</i> , 2019, 115, 46-52.	1.2	19
45	Accelerated 3D T ₂ -weighted imaging of the prostate with 1mm isotropic resolution in less than 3 minutes. <i>Magnetic Resonance in Medicine</i> , 2019, 82, 721-731.	1.9	11
46	Transcriptomic profiling reveals three molecular phenotypes of adenocarcinoma at the gastroesophageal junction. <i>International Journal of Cancer</i> , 2019, 145, 3389-3401.	2.3	17
47	Adaptive statistical iterative reconstruction (ASIR) affects CT radiomics quantification in primary colorectal cancer. <i>European Radiology</i> , 2019, 29, 5227-5235.	2.3	27
48	The National Institute for Health Research: making an impact in imaging research. <i>Clinical Radiology</i> , 2019, 74, 242-246.	0.5	3
49	Exploratory radiomic features from integrated 18F-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging are associated with contemporaneous metastases in oesophageal/gastroesophageal cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1478-1484.	3.3	17
50	Patient preferences for whole-body MRI or conventional staging pathways in lung and colorectal cancer: a discrete choice experiment. <i>European Radiology</i> , 2019, 29, 3889-3900.	2.3	20
51	MRI heterogeneity analysis for prediction of recurrence and disease free survival in anal cancer. <i>Radiotherapy and Oncology</i> , 2019, 134, 119-126.	0.3	15
52	Prediction of a positive circumferential resection margin at surgery following neoadjuvant chemotherapy for adenocarcinoma of the oesophagus. <i>BJS Open</i> , 2019, 3, 767-776.	0.7	3
53	Measurement of 18F-FDG PET tumor heterogeneity improves early assessment of response to bevacizumab compared with the standard size and uptake metrics in a colorectal cancer model. <i>Nuclear Medicine Communications</i> , 2019, 40, 611-617.	0.5	7
54	Does Measurement of First-Order and Heterogeneity Parameters Improve Response Assessment of Bone Metastases in Breast Cancer Compared to SUVmax in [18F]fluoride and [18F]FDG PET?. <i>Molecular Imaging and Biology</i> , 2019, 21, 781-789.	1.3	11

#	ARTICLE	IF	CITATIONS
55	Learning to detect chest radiographs containing pulmonary lesions using visual attention networks. <i>Medical Image Analysis</i> , 2019, 53, 26-38.	7.0	77
56	Accelerated 3D T ₂ mapping with dictionary-based matching for prostate imaging. <i>Magnetic Resonance in Medicine</i> , 2019, 81, 1795-1805.	1.9	16
57	Prediction of therapy response in bone-predominant metastatic breast cancer: comparison of [18F] fluorodeoxyglucose and [18F]-fluoride PET/CT with whole-body MRI with diffusion-weighted imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 821-830.	3.3	31
58	Whole-body MRI compared with standard pathways for staging metastatic disease in lung and colorectal cancer: the Streamline diagnostic accuracy studies. <i>Health Technology Assessment</i> , 2019, 23, 1-270.	1.3	34
59	Anal Canal. , 2019, , 77-85.		0
60	Reply: Relevance of Measurement Uncertainty for Quantitative Response Assessment of Breast Cancer Bone Metastases with ¹⁸ F-Fluoride. <i>Journal of Nuclear Medicine</i> , 2019, 60, 569.1-569.	2.8	4
61	Characterization of Small Renal Tumors With Magnetic Resonance Elastography. <i>Investigative Radiology</i> , 2018, 53, 344-351.	3.5	14
62	Functional and Hybrid Imaging of Bone Metastases. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 961-972.	3.1	18
63	Imaging α 5 β 1 integrin expression in skeletal metastases with ^{99m} Tc-maraciclalide single-photon emission computed tomography: detection and therapy response assessment. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 898-903.	3.3	9
64	Rationale and design of the SMaRT trial: A randomised, prospective, parallel, non-blinded, one-centre trial to evaluate the use of magnetic resonance imaging in acute setting in patients presenting with suspected scaphoid fracture. <i>Clinical Trials</i> , 2018, 15, 120-129.	0.7	4
65	Challenges and Promises of PET Radiomics. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 1083-1089.	0.4	121
66	Imaging of Tumour Heterogeneity: Functional MR Techniques in Oncology. , 2018, , 131-150.		0
67	Comparison of whole body magnetic resonance imaging (WBMRI) to whole body computed tomography (WBCT) or ¹⁸ F-fluorodeoxyglucose positron emission tomography/CT (¹⁸ F-FDG PET/CT) in patients with myeloma: Systematic review of diagnostic performance. <i>Critical Reviews in Oncology/Hematology</i> . 2018. 124. 66-72.	2.0	43
68	UK quantitative WB-DWI technical workgroup: consensus meeting recommendations on optimisation, quality control, processing and analysis of quantitative whole-body diffusion-weighted imaging for cancer. <i>British Journal of Radiology</i> , 2018, 91, 20170577.	1.0	70
69	Weight-adapted iodinated contrast media administration in abdomino-pelvic CT: Can image quality be maintained?. <i>Radiography</i> , 2018, 24, 22-27.	1.1	16
70	The economic evidence for advanced imaging in the diagnosis of suspected scaphoid fractures: systematic review of evidence. <i>Journal of Hand Surgery: European Volume</i> , 2018, 43, 642-651.	0.5	11
71	The impact of MRI sequence on tumour staging and gross tumour volume delineation in squamous cell carcinoma of the anal canal. <i>European Radiology</i> , 2018, 28, 1512-1519.	2.3	21
72	Investigating the histopathologic correlates of ¹⁸ F-FDG PET heterogeneity in non-small-cell lung cancer. <i>Nuclear Medicine Communications</i> , 2018, 39, 1197-1206.	0.5	13

#	ARTICLE	IF	CITATIONS
73	Identification of Prognostic Phenotypes of Esophageal Adenocarcinoma in 2 Independent Cohorts. <i>Gastroenterology</i> , 2018, 155, 1720-1728.e4.	0.6	67
74	Novel imaging techniques in staging oesophageal cancer. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2018, 36-37, 17-25.	1.0	29
75	BACCHUS: A randomised non-comparative phase II study of neoadjuvant chemotherapy (NACT) in patients with locally advanced rectal cancer (LARC). <i>Heliyon</i> , 2018, 4, e00804.	1.4	21
76	Added Value of Contrast-Enhanced T1-Weighted and Diffusion-Weighted Sequences for Characterization of Incidental Findings on Whole Body Magnetic Resonance Imaging in Plasma-Cell Disorders. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 822-828.	0.2	4
77	National survey of imaging practice for suspected or confirmed plasma cell malignancies. <i>British Journal of Radiology</i> , 2018, 91, 20180462.	1.0	5
78	Imaging for the diagnosis and response assessment of renal tumours. <i>World Journal of Urology</i> , 2018, 36, 1927-1942.	1.2	59
79	Imaging biomarkers in oncology: Basics and application to MRI. <i>Journal of Magnetic Resonance Imaging</i> , 2018, 48, 13-26.	1.9	39
80	IntAct: intraoperative fluorescence angiography to prevent anastomotic leak in rectal cancer surgery: a randomized controlled trial. <i>Colorectal Disease</i> , 2018, 20, O226-O234.	0.7	83
81	Is there a role for perfusion imaging in assessing treatment response following ablative therapy of small renal masses? A systematic review. <i>European Journal of Radiology Open</i> , 2018, 5, 102-107.	0.7	0
82	Perfusion CT: Technical Aspects. <i>Medical Radiology</i> , 2017, , 121-129.	0.0	0
83	Post Brexit: challenges and opportunities for radiology beyond the European Union. <i>British Journal of Radiology</i> , 2017, 90, 20160852.	1.0	2
84	Primary Rectal Cancer: Repeatability of Global and Local-Regional MR Imaging Texture Features. <i>Radiology</i> , 2017, 284, 552-561.	3.6	66
85	Magnetic Resonance Imaging (MRI) of Intratumoral Voxel Heterogeneity as a Potential Response Biomarker: Assessment in a HER2+ Esophageal Adenocarcinoma Xenograft Following Trastuzumab and/or Cisplatin Therapy. <i>Translational Oncology</i> , 2017, 10, 459-467.	1.7	2
86	Evaluation of treatment response and resistance in metastatic renal cell cancer (mRCC) using integrated 18F-Fluorodeoxyglucose (18F-FDG) positron emission tomography/magnetic resonance imaging (PET/MRI); The REMAP study. <i>BMC Cancer</i> , 2017, 17, 392.	1.1	14
87	The effect of post-injection 18F-FDG PET scanning time on texture analysis of peripheral nerve sheath tumours in neurofibromatosis-1. <i>EJNMMI Research</i> , 2017, 7, 35.	1.1	16
88	Streamlining staging of lung and colorectal cancer with whole body MRI; study protocols for two multicentre, non-randomised, single-arm, prospective diagnostic accuracy studies (Streamline C and) Tj ETQq0 0 0 igBT /Overdock 10 Tf		
89	Characterisation of malignant peripheral nerve sheath tumours in neurofibromatosis-1 using heterogeneity analysis of 18F-FDG PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1845-1852.	3.3	21
90	P1.03-024 Accuracy of Combined Semantic and Computational CT Features in Predicting Non-Small Cell Lung Cancer Subtype. <i>Journal of Thoracic Oncology</i> , 2017, 12, S556-S557.	0.5	0

#	ARTICLE	IF	CITATIONS
91	Biomarkers in anal cancer: from biological understanding to stratified treatment. British Journal of Cancer, 2017, 116, 156-162.	2.9	46
92	PET/MRIâ€”knocking on the doors of the rich and famous. British Journal of Radiology, 2017, 90, 20170347.	1.0	7
93	Association of Coloproctology of Great Britain & Ireland (<scp>ACPGBI</scp>): Guidelines for the Management of Cancer of the Colon, Rectum and Anus (2017) â€” Multidisciplinary Management. Colorectal Disease, 2017, 19, 37-66.	0.7	77
94	Association of Coloproctology of Great Britain & Ireland (<scp>ACPGBI</scp>): Guidelines for the Management of Cancer of the Colon, Rectum and Anus (2017) â€” Anal Cancer. Colorectal Disease, 2017, 19, 82-97.	0.7	45
95	Guidelines for the use of imaging in the management of patients with myeloma. British Journal of Haematology, 2017, 178, 380-393.	1.2	101
96	Adaptive statistical iterative reconstruction improves image quality without affecting perfusion CT quantitation in primary colorectal cancer. European Journal of Radiology Open, 2017, 4, 69-74.	0.7	7
97	Imaging biomarker roadmap for cancer studies. Nature Reviews Clinical Oncology, 2017, 14, 169-186.	12.5	792
98	The effects of segmentation algorithms on the measurement of 18F-FDG PET texture parameters in non-small cell lung cancer. EJNMMI Research, 2017, 7, 60.	1.1	50
99	Challenges in imaging assessment following liver stereotactic body radiotherapy: pitfalls to avoid in clinical practice. Chinese Clinical Oncology, 2017, 6, S11-S11.	0.4	10
100	An Incidental Renal Oncocytoma: 18F-Choline PET/MRI. Diagnostics, 2016, 6, 14.	1.3	0
101	Molecular and Functional Imaging of Bone Metastases in Breast and Prostate Cancers. Clinical Nuclear Medicine, 2016, 41, e44-e50.	0.7	30
102	Imaging Heterogeneity in Lung Cancer: Techniques, Applications, and Challenges. American Journal of Roentgenology, 2016, 207, 534-543.	1.0	121
103	Imaging Bone Metastases in Breast Cancer: Staging and Response Assessment. Journal of Nuclear Medicine, 2016, 57, 27S-33S.	2.8	84
104	The role of new PET tracers for lung cancer. Lung Cancer, 2016, 94, 7-14.	0.9	47
105	Positron Emission Tomography/Magnetic Resonance Imaging of Gastrointestinal Cancers. Seminars in Ultrasound, CT and MRI, 2016, 37, 352-357.	0.7	4
106	Clinical significance of hypoxia in nasopharyngeal carcinoma with a focus on existing and novel hypoxia molecular imaging. Chinese Clinical Oncology, 2016, 5, 24-24.	0.4	4
107	Pathological heterogeneity after trastuzumab and combination chemotherapy in HER2+ gastroesophageal adenocarcinoma xenograft.. Journal of Clinical Oncology, 2016, 34, 42-42.	0.8	0
108	Water-fat separation in diffusion-weighted EPI using an IDEAL approach with image navigator. Magnetic Resonance in Medicine, 2015, 73, 964-972.	1.9	15

#	ARTICLE	IF	CITATIONS
109	Imaging Tumor Response and Tumoral Heterogeneity in Non-Small Cell Lung Cancer Treated With Antiangiogenic Therapy. <i>Journal of Thoracic Imaging</i> , 2015, 30, 300-307.	0.8	12
110	PET/MRI in Oncological Imaging: State of the Art. <i>Diagnostics</i> , 2015, 5, 333-357.	1.3	37
111	Predicting Response to Neoadjuvant Chemotherapy with PET Imaging Using Convolutional Neural Networks. <i>PLoS ONE</i> , 2015, 10, e0137036.	1.1	139
112	The precision of textural analysis in 18F-FDG-PET scans of oesophageal cancer. <i>European Radiology</i> , 2015, 25, 2805-2812.	2.3	66
113	Non-Small Cell Lung Cancer Treated with Erlotinib: Heterogeneity of ¹⁸ F-FDG Uptake at PET—Association with Treatment Response and Prognosis. <i>Radiology</i> , 2015, 276, 883-893.	3.6	147
114	Molecular imaging of hypoxia in non-small-cell lung cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 956-976.	3.3	50
115	Bench to bedside molecular functional imaging in translational cancer medicine: to image or to imagine?. <i>Clinical Radiology</i> , 2015, 70, 1060-1082.	0.5	54
116	Texture analysis of 125I-A5B7 anti-CEA antibody SPECT differentiates metastatic colorectal cancer model phenotypes and anti-vascular therapy response. <i>British Journal of Cancer</i> , 2015, 112, 1882-1887.	2.9	19
117	Perfusion CT imaging of treatment response in oncology. <i>European Journal of Radiology</i> , 2015, 84, 2380-2385.	1.2	46
118	Imaging body composition in cancer patients: visceral obesity, sarcopenia and sarcopenic obesity may impact on clinical outcome. <i>Insights Into Imaging</i> , 2015, 6, 489-497.	1.6	149
119	Assessment of changes in tumor heterogeneity following neoadjuvant chemotherapy in primary esophageal cancer. <i>Ecological Management and Restoration</i> , 2015, 28, 172-179.	0.2	77
120	Bone metastases in prostate cancer: which scan?. <i>BJU International</i> , 2014, 114, 792-793.	1.3	0
121	Automatic region-of-interest segmentation and registration of dynamic contrast-enhanced images of colorectal tumors. <i>Physics in Medicine and Biology</i> , 2014, 59, 7361-7381.	1.6	3
122	Primary Esophageal Cancer: Heterogeneity as Potential Prognostic Biomarker in Patients Treated with Definitive Chemotherapy and Radiation Therapy. <i>Radiology</i> , 2014, 270, 141-148.	3.6	184
123	Changes in Primary Breast Cancer Heterogeneity May Augment Midtreatment MR Imaging Assessment of Response to Neoadjuvant Chemotherapy. <i>Radiology</i> , 2014, 272, 100-112.	3.6	113
124	Hidradenitis Suppurativa. <i>Diseases of the Colon and Rectum</i> , 2014, 57, 762-771.	0.7	35
125	Imaging Assessment of Lung Tumor Angiogenesis: Insights and Innovations. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2014, 35, 112-128.	0.8	2
126	Still a long way to go to achieve multidisciplinary for the benefit of patients: commentary on the ESMO position paper (<i>Annals of Oncology</i> 25(1): 9-15, 2014). <i>Annals of Oncology</i> , 2014, 25, 1863-1865.	0.6	5

#	ARTICLE	IF	CITATIONS
127	The association of 18F-FDG PET/CT parameters with survival in malignant pleural mesothelioma. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 276-282.	3.3	59
128	Rectal tumour volume (GTV) delineation using T2-weighted and diffusion-weighted MRI: Implications for radiotherapy planning. European Journal of Radiology, 2014, 83, 768-772.	1.2	28
129	Assessment of sarcopenia and changes in body composition after neoadjuvant chemotherapy and associations with clinical outcomes in oesophageal cancer. European Radiology, 2014, 24, 998-1005.	2.3	181
130	MRI of anal cancer: assessing response to definitive chemoradiotherapy. Abdominal Imaging, 2014, 39, 2-17.	2.0	23
131	Quality control within the multicentre perfusion CT study of primary colorectal cancer (PROSPeCT): results of an iodine density phantom study. European Radiology, 2014, 24, 2309-2318.	2.3	4
132	Perfusion CT imaging of colorectal cancer. British Journal of Radiology, 2014, 87, 20130811.	1.0	25
133	Multifunctional Imaging Signature for V-KI-RAS2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutations in Colorectal Cancer. Journal of Nuclear Medicine, 2014, 55, 386-391.	2.8	74
134	Radiomics in PET: principles and applications. Clinical and Translational Imaging, 2014, 2, 269-276.	1.1	103
135	Anal cancer: ESMOâ€™SSOâ€™ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Radiotherapy and Oncology, 2014, 111, 330-339.	0.3	179
136	Perfusion CT: Principles, Technical Aspects and Applications in Oncology. , 2014, , 325-340.		1
137	Correlation of Intra-Tumor 18F-FDG Uptake Heterogeneity Indices with Perfusion CT Derived Parameters in Colorectal Cancer. PLoS ONE, 2014, 9, e99567.	1.1	30
138	How to Select for Preoperative Short-course Radiotherapy, While Considering Long-course Chemoradiotherapy or Immediate Surgery, and Who Benefits?. European Oncology and Haematology, 2014, 10, 17.	0.0	6
139	Assessment of tumoral heterogeneity in NSCLC treated with bevacizumab: A prospective study.. Journal of Clinical Oncology, 2014, 32, e19124-e19124.	0.8	0
140	Changes in tumour vessel density upon treatment with anti-angiogenic agents: relationship with response and resistance to therapy. British Journal of Cancer, 2013, 109, 1230-1242.	2.9	42
141	Functional Imaging of the Liver. Seminars in Ultrasound, CT and MRI, 2013, 34, 54-65.	0.7	13
142	Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Research, 2013, 15, R92.	2.2	320
143	The Role of Hepatocyte-Specific Contrast Agents in Hepatobiliary Magnetic Resonance Imaging. Seminars in Ultrasound, CT and MRI, 2013, 34, 44-53.	0.7	23
144	Quantifying tumour heterogeneity in 18F-FDG PET/CT imaging by texture analysis. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 133-140.	3.3	395

#	ARTICLE	IF	CITATIONS
145	CT Perfusion in Oncologic Imaging: A Useful Tool?. American Journal of Roentgenology, 2013, 200, 8-19.	1.0	146
146	Assessment of tumor heterogeneity by CT texture analysis: Can the largest cross-sectional area be used as an alternative to whole tumor analysis?. European Journal of Radiology, 2013, 82, 342-348.	1.2	323
147	Functional imaging of the bowel. Abdominal Imaging, 2013, 38, 1203-1213.	2.0	2
148	Reproducibility of Dynamic Contrast-enhanced MR Imaging: Why We Should Care. Radiology, 2013, 266, 698-700.	3.6	18
149	Primary Colorectal Cancer: Use of Kinetic Modeling of Dynamic Contrast-enhanced CT Data to Predict Clinical Outcome. Radiology, 2013, 267, 145-154.	3.6	25
150	Assessment of Primary Colorectal Cancer Heterogeneity by Using Whole-Tumor Texture Analysis: Contrast-enhanced CT Texture as a Biomarker of 5-year Survival. Radiology, 2013, 266, 177-184.	3.6	384
151	Are Pretreatment ¹⁸ F-FDG PET Tumor Textural Features in Non-Small Cell Lung Cancer Associated with Response and Survival After Chemoradiotherapy?. Journal of Nuclear Medicine, 2013, 54, 19-26.	2.8	361
152	Non-Small Cell Lung Cancer: Histopathologic Correlates for Texture Parameters at CT. Radiology, 2013, 266, 326-336.	3.6	384
153	Fluorodeoxyglucose positron emission tomography (¹⁸ F-FDG PET)/computed tomography (CT) in bladder cancer. BJU International, 2013, 112, 709-709.	1.3	1
154	Body composition and association with treatment toxicity in patients with advanced renal cell carcinoma receiving targeted agents.. Journal of Clinical Oncology, 2013, 31, e15608-e15608.	0.8	0
155	Imaging assessment of desmoid tumours in familial adenomatous polyposis: is state-of-the-art 1.5 T MRI better than 64-MDCT?. British Journal of Radiology, 2012, 85, e254-e261.	1.0	29
156	The Flow-Metabolic Phenotype of Primary Colorectal Cancer: Assessment by Integrated ¹⁸ F-FDG PET/Perfusion CT with Histopathologic Correlation. Journal of Nuclear Medicine, 2012, 53, 687-692.	2.8	29
157	Phase Ib trial of radiotherapy in combination with combretastatin-A4-phosphate in patients with non-small-cell lung cancer, prostate adenocarcinoma, and squamous cell carcinoma of the head and neck. Annals of Oncology, 2012, 23, 231-237.	0.6	68
158	Integrated ¹⁸ F-FDG PET/CT and Perfusion CT of Primary Colorectal Cancer: Effect of Inter- and Intraobserver Agreement on Metabolic-Vascular Parameters. American Journal of Roentgenology, 2012, 199, 1003-1009.	1.0	15
159	Operable Non-Small Cell Lung Cancer: Correlation of Volumetric Helical Dynamic Contrast-enhanced CT Parameters with Immunohistochemical Markers of Tumor Hypoxia. Radiology, 2012, 264, 581-589.	3.6	47
160	Can Combined ¹⁸ F-FDG-PET and Dynamic Contrast-Enhanced MRI Predict Behavior of Desmoid Tumors in Patients With Familial Adenomatous Polyposis?. Diseases of the Colon and Rectum, 2012, 55, 1032-1037.	0.7	10
161	Functional Computed Tomography Imaging. Investigative Radiology, 2012, 47, 1.	3.5	4
162	Computed Tomography Perfusion Imaging for Therapeutic Assessment. Investigative Radiology, 2012, 47, 2-4.	3.5	39

#	ARTICLE	IF	CITATIONS
163	Predicting response to neoadjuvant chemotherapy in primary breast cancer using volumetric helical perfusion computed tomography: a preliminary study. <i>European Radiology</i> , 2012, 22, 1871-1880.	2.3	10
164	Perfusion CT assessment of the colon and rectum: Feasibility of quantification of bowel wall perfusion and vascularization. <i>European Journal of Radiology</i> , 2012, 81, 821-824.	1.2	18
165	Diffusion tensor imaging (DTI) of desmoid tumours in familial adenomatous polyposis: Initial experience. <i>European Journal of Radiology</i> , 2012, 81, 3646-3651.	1.2	3
166	Assessment of tumor heterogeneity: an emerging imaging tool for clinical practice?. <i>Insights Into Imaging</i> , 2012, 3, 573-589.	1.6	738
167	Reproducibility of 2D and 3D Fractal Analysis Techniques for the Assessment of Spatial Heterogeneity of Regional Blood Flow in Rectal Cancer. <i>Radiology</i> , 2012, 263, 865-873.	3.6	36
168	Diffusion tensor imaging of the anal canal at 3 tesla: Feasibility and reproducibility of anisotropy measures. <i>Journal of Magnetic Resonance Imaging</i> , 2012, 35, 820-826.	1.9	14
169	Current status and guidelines for the assessment of tumour vascular support with dynamic contrast-enhanced computed tomography. <i>European Radiology</i> , 2012, 22, 1430-1441.	2.3	180
170	Assessment of the metabolic flow phenotype of primary colorectal cancer: correlations with microvessel density are influenced by the histological scoring method. <i>European Radiology</i> , 2012, 22, 1687-1692.	2.3	14
171	Novel Oncologic Drugs: What They Do and How They Affect Images. <i>Radiographics</i> , 2011, 31, 2059-2091.	1.4	71
172	Commercial software upgrades may significantly alter Perfusion CT parameter values in colorectal cancer. <i>European Radiology</i> , 2011, 21, 744-749.	2.3	33
173	Radiation dose from volumetric helical perfusion CT of the thorax, abdomen or pelvis. <i>European Radiology</i> , 2011, 21, 974-981.	2.3	44
174	Assessment of Response to Tyrosine Kinase Inhibitors in Metastatic Renal Cell Cancer: CT Texture as a Predictive Biomarker. <i>Radiology</i> , 2011, 261, 165-171.	3.6	328
175	Investigating Vulnerable Atheroma Using Combined ¹⁸ F-FDG PET/CT Angiography of Carotid Plaque with Immunohistochemical Validation. <i>Journal of Nuclear Medicine</i> , 2011, 52, 1698-1703.	2.8	69
176	Angiogenesis in Non-small Cell Lung Cancer. <i>Journal of Thoracic Imaging</i> , 2010, 25, 142-150.	0.8	23
177	Reply to letter to the editor: Assessment of the spatial pattern of colorectal tumour perfusion estimated at perfusion CT using two-dimensional fractal analysis. <i>European Radiology</i> , 2010, 20, 120-120.	2.3	0
178	Magnetic Resonance Imaging Assessment of Squamous Cell Carcinoma of the Anal Canal Before and After Chemoradiation: Can MRI Predict for Eventual Clinical Outcome?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, 715-721.	0.4	62
179	The Role of Functional Imaging in Colorectal Cancer. <i>American Journal of Roentgenology</i> , 2010, 195, 54-66.	1.0	56
180	CT response assessment combining reduction in both size and arterial phase density correlates with time to progression in metastatic renal cancer patients treated with targeted therapies. <i>Cancer Biology and Therapy</i> , 2010, 9, 15-19.	1.5	108

#	ARTICLE	IF	CITATIONS
181	Quantitative helical dynamic contrast enhanced computed tomography assessment of the spatial variation in whole tumour blood volume with radiotherapy in lung cancer. <i>Lung Cancer</i> , 2010, 69, 71-76.	0.9	16
182	Dynamic Contrast-Enhanced and Diffusion-Weighted MRI of the Gastrointestinal Tract. <i>Medical Radiology</i> , 2010, , 51-63.	0.0	1
183	Imaging for staging and response assessment in rectal cancer. <i>Current Colorectal Cancer Reports</i> , 2009, 5, 224-231.	1.0	0
184	Can perfusion CT assessment of primary colorectal adenocarcinoma blood flow at staging predict for subsequent metastatic disease? A pilot study. <i>European Radiology</i> , 2009, 19, 79-89.	2.3	82
185	Assessment of the spatial pattern of colorectal tumour perfusion estimated at perfusion CT using two-dimensional fractal analysis. <i>European Radiology</i> , 2009, 19, 1358-1365.	2.3	59
186	Effect of intravenous contrast agent volume on colorectal cancer vascular parameters as measured by perfusion computed tomography. <i>Clinical Radiology</i> , 2009, 64, 368-372.	0.5	11
187	Functional Imaging of Colorectal Cancer: Positron Emission Tomography, Magnetic Resonance Imaging, and Computed Tomography. <i>Clinical Colorectal Cancer</i> , 2009, 8, 77-87.	1.0	18
188	Quantitative Assessment of Colorectal Cancer Perfusion: Perfusion Computed Tomography and Dynamic Contrast Enhanced Magnetic Resonance Imaging. , 2009, , 183-205.		0
189	Functional imaging of colorectal cancer: positron emission tomography, magnetic resonance imaging, and computed tomography. <i>Clinical Colorectal Cancer</i> , 2009, 8, 77-87.	1.0	0
190	CT coronary angiography: Quantitative assessment of myocardial perfusion using test bolus dataâ€‘initial experience. <i>European Radiology</i> , 2008, 18, 2155-2163.	2.3	20
191	Quantitative Assessment of Colorectal Cancer Tumor Vascular Parameters by Using Perfusion CT: Influence of Tumor Region of Interest. <i>Radiology</i> , 2008, 247, 726-732.	3.6	81
192	Colorectal Tumor Vascularity: Quantitative Assessment with Multidetector CTâ€‘Do Tumor Perfusion Measurements Reflect Angiogenesis?. <i>Radiology</i> , 2008, 249, 510-517.	3.6	128
193	Effect of Temporal Interval Between Scan Acquisitions on Quantitative Vascular Parameters in Colorectal Cancer: Implications for Helical Volumetric Perfusion CT Techniques. <i>American Journal of Roentgenology</i> , 2008, 191, W288-W292.	1.0	35
194	Differentiation between Diverticulitis and Colorectal Cancer: Quantitative CT Perfusion Measurements versus Morphologic Criteriaâ€‘Initial Experience. <i>Radiology</i> , 2007, 242, 456-462.	3.6	120
195	Leukocyte DNA Damage after Multiâ€‘Detector Row CT: A Quantitative Biomarker of Low-Level Radiation Exposure. <i>Radiology</i> , 2007, 242, 244-251.	3.6	208
196	Quantitative Tumor Perfusion Assessment with Multidetector CT: Are Measurements from Two Commercial Software Packages Interchangeable?. <i>Radiology</i> , 2007, 242, 777-782.	3.6	120
197	Effect of nitric-oxide synthesis on tumour blood volume and vascular activity: a phase I study. <i>Lancet Oncology</i> , The, 2007, 8, 111-118.	5.1	105
198	Functional imaging of colorectal cancer angiogenesis. <i>Lancet Oncology</i> , The, 2007, 8, 245-255.	5.1	92

#	ARTICLE	IF	CITATIONS
199	Acute tumor vascular effects following fractionated radiotherapy in human lung cancer: In vivo whole tumor assessment using volumetric perfusion computed tomography. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 67, 417-424.	0.4	78
200	Tumor Antivascular Effects of Radiotherapy Combined with Combretastatin A4 Phosphate in Human Non-Small-Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 67, 1375-1380.	0.4	73
201	Imaging tumor angiogenesis: functional assessment using MDCT or MRI?. <i>Abdominal Imaging</i> , 2006, 31, 194-199.	2.0	70
202	Polyp Detection with CT Colonography: Primary 3D Endoluminal Analysis versus Primary 2D Transverse Analysis with Computer-assisted Reader Software. <i>Radiology</i> , 2006, 239, 759-767.	3.6	53
203	Quantitative Assessment of Tissue Perfusion Using MDCT: Comparison of Colorectal Cancer and Skeletal Muscle Measurement Reproducibility. <i>American Journal of Roentgenology</i> , 2006, 187, 164-169.	1.0	70
204	Quantitative Assessment of Lung Cancer Perfusion Using MDCT: Does Measurement Reproducibility Improve with Greater Tumor Volume Coverage?. <i>American Journal of Roentgenology</i> , 2006, 187, 1079-1084.	1.0	72
205	Quantitative colorectal cancer perfusion measurement by multidetector-row CT: does greater tumour coverage improve measurement reproducibility?. <i>British Journal of Radiology</i> , 2006, 79, 578-583.	1.0	28
206	Lung Cancer Perfusion at Multi-Detector Row CT: Reproducibility of Whole Tumor Quantitative Measurements. <i>Radiology</i> , 2006, 239, 547-553.	3.6	132
207	Quantitative Colorectal Cancer Perfusion Measurement Using Dynamic Contrast-Enhanced Multidetector-Row Computed Tomography. <i>Journal of Computer Assisted Tomography</i> , 2005, 29, 59-63.	0.5	65
208	Imaging breast cancer response during neoadjuvant systemic therapy. <i>Expert Review of Anticancer Therapy</i> , 2005, 5, 893-905.	1.1	23
209	Quantitative Assessment of Colorectal Cancer Perfusion Using MDCT: Inter- and Intraobserver Agreement. <i>American Journal of Roentgenology</i> , 2005, 185, 225-231.	1.0	68
210	Is direct radiologist supervision of abdominal computed tomography (CT) scans necessary?. <i>Clinical Radiology</i> , 2005, 60, 758-761.	0.5	2
211	Local radiological staging of rectal cancer. <i>Clinical Radiology</i> , 2004, 59, 215-226.	0.5	40
212	Optimizing Bowel Preparation for Multidetector Row CT Colonography: Effect of Citramag and Picolax. <i>Clinical Radiology</i> , 2003, 58, 723-732.	0.5	29
213	Optimizing Colonic Distention for Multi-Detector Row CT Colonography: Effect of Hyoscine Butylbromide and Rectal Balloon Catheter. <i>Radiology</i> , 2003, 229, 99-108.	3.6	164
214	The Therapeutic Impact of Abdominal Ultrasound in Patients with Acute Abdominal Symptoms. <i>Clinical Radiology</i> , 2002, 57, 268-271.	0.5	42
215	Dynamic MR Imaging of the Pelvic Floor in Asymptomatic Subjects. <i>American Journal of Roentgenology</i> , 2000, 174, 661-666.	1.0	141
216	Editorial Comment: Artificial Intelligence for Lung Nodules—Progress, But Is It Enough?. <i>American Journal of Roentgenology</i> , 0, . .	1.0	0